Evoke Pharma Inc corporate insiders have only been selling lately: one insider sold about $96,000 of stock over 12 months, with no open-market purchases.
Keep in mind most insider selling is routine — stock-based pay has to be converted to cash at some point.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 7, 2025 | Klein Roger M. | 10% Owner | Sell | 5,000 | $10.66 | $53K | SEC |
| Nov 7, 2025 | Klein Roger M. | 10% Owner | Sell | 4,000 | $10.65 | $43K | SEC |
| Jan 30, 2025 | Mack Daniel | 10% Owner | Sell | 41 | $4.39 | $180 | SEC |
In the last 12 months Evoke Pharma Inc insiders made open-market purchases worth about $0 and sales worth about $96,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in EVOK was filed on 2025-11-07.
No congressional trades in EVOK were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).